m+Medelevator.RU
← Поиск публикаций
Current opinion in rheumatology · 2010

Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis.

СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Witko-Sarsat Véronique, Reuter Nathalie, Mouthon Luc

Аннотация

PURPOSE OF REVIEW: This review focuses on proteinase 3 (PR3), the preferred target of antineutrophil cytoplasmic antibodies (ANCAs) in Wegener's granulomatosis. Deciphering the molecular associations that PR3 can make with its cognate partners might help to understand its pathophysiological significance in Wegener's granulomatosis and the potential role of ANCA as modulator of PR3 functions.

RECENT FINDINGS: In neutrophils, PR3 is mainly localized within azurophilic granules but is also detected at the plasma membrane. Among PR3 partners (CD16, CD11b/CD18), CD177, a glycosylphosphatidylinositol (GPI)-anchored membrane protein is a potential receptor for PR3. In addition, PR3 can be externalized at the plasma membrane at a very early stage of neutrophil apoptosis, in the absence of degranulation. In these conditions, PR3 is associated with specific partners including phospholipidscramblase-1 and calreticulin. Interestingly, apoptosis-induced PR3 membrane expression significantly impaired macrophage phagocytosis. This new role of PR3 acting as a 'don't eat me signal' that delays neutrophil clearance might potentiate inflammation and autoimmunity.

SUMMARY: Since PR3 membrane expression seems to represent a key element in the inflammatory and autoimmunity process, elucidation of the molecular basis of PR3 interaction with the plasma membrane or with receptor proteins led to the possibility of targeted therapy.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты